Skip to Content
Merck
CN
  • Adverse effect of obesity on red cell membrane arachidonic and docosahexaenoic acids in gestational diabetes.

Adverse effect of obesity on red cell membrane arachidonic and docosahexaenoic acids in gestational diabetes.

Diabetologia (2003-11-25)
Y Min, K Ghebremeskel, C Lowy, B Thomas, M A Crawford
ABSTRACT

Gestational diabetes is a metabolic disorder affecting 2-5% of women and is a predictor of obesity, Type 2 diabetes mellitus and cardiovascular disease. Insulin resistance, a characteristic of gestational diabetes and obesity, is correlated with the fatty acids profile of the red cell and skeletal muscle membranes. We investigated the plasma and red cell fatty acid status of gestational diabetes. The effect of obesity on membrane fatty acids was also examined. Fasting blood obtained at diagnosis was analysed for the fatty acids in plasma choline phosphoglycerides and red cell choline and ethanolamine phosphoglycerides. There were reductions in arachidonic acid (controls 10.74+/-2.35 vs gestational diabetes 8.35+/-3.49, p<0.01) and docosahexaenoic acid (controls 6.31+/-2.67 vs gestational diabetes 3.25+/-2.00, p<0.0001) in the red cell choline phosphoglycerides in gestational diabetes. A similar pattern was found in the ethanolamine phosphoglycerides. Moreover, the arachidonic and docosahexaenoic acids depletion in the red cell choline phosphoglycerides was much greater in overweight/obese gestational diabetes (arachidonic acid=7.49+/-3.37, docosahexaenoic acid=2.98+/-2.18, p<0.01) compared with lean gestational diabetes (arachidonic acid=10.03+/-2.74, docosahexaenoic acid=4.18+/-1.42). Apparently normal plasma choline phosphoglycerides fatty acids profile in the gestational diabetic women suggested that membrane lipid abnormality is associated specifically with perturbation in the membrane. The fact that the lipid abnormality is more pronounced in the outer leaflet of the membrane where most of receptor binding and enzyme activities take place might provide an explanation for the increased insulin resistance in gestational diabetes and obesity.

MATERIALS
Product Number
Brand
Product Description

Supelco
Palmitic acid, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sigma-Aldrich
Linoleic acid, technical, 58-74% (GC)
Supelco
Linoleic acid, analytical standard
Sigma-Aldrich
Palmitic acid, ≥98%, FCC, FG
Sigma-Aldrich
Palmitic acid, ≥98% palmitic acid basis (GC)
Supelco
Palmitic acid, analytical standard
Sigma-Aldrich
Palmitic acid, BioXtra, ≥99%
Sigma-Aldrich
Linoleic acid, ≥98%
Sigma-Aldrich
Palmitic acid, ≥99%
Sigma-Aldrich
Linoleic acid, liquid, BioReagent, suitable for cell culture
Supelco
Palmitic acid, Pharmaceutical Secondary Standard; Certified Reference Material
Palmitic acid, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Palmitic acid, natural, 98%, FG
Sigma-Aldrich
Arachidonic acid, from non-animal source, ≥98.5% (GC)
Supelco
Oleic acid, analytical standard
Sigma-Aldrich
Arachidonic acid, >95.0% (GC)
Sigma-Aldrich
Oleic acid, meets analytical specification of Ph, Eur., 65.0-88.0% (GC)
Sigma-Aldrich
Oleic acid, natural, FCC
Sigma-Aldrich
Oleic acid, suitable for cell culture, BioReagent
Sigma-Aldrich
Oleic acid, ≥99% (GC)
Supelco
Oleic acid, Selectophore, ≥99%
Sigma-Aldrich
Oleic acid, technical grade, 90%